SETHIKA CARE Pharmacy
Fenoget 200 200 mg
Last updated 24/05/2026 at 02:11
Licensed pharmacy partner
SETHIKA CARE Pharmacy
271 Yothapol Khemarak Phoumin Blvd (271), Phnom Penh, Cambodia
Prescription notice
Item may require a valid prescription. Please consult your doctor or pharmacist before using new medication.
Indication
Fenoget 200 contains Fenofibrate, a fibric acid derivative lipid-lowering agent used as adjunct to diet for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia to reduce cardiovascular risk.
Ingredients
- Fenofibrate 200 mg (micronised)
Direction
Adults: 200 mg once daily orally with a meal. Swallow the capsule whole.
Side effects
- Common: nausea
- diarrhoea
- abdominal pain
- dyspepsia.
- Common: headache
- fatigue.
- Uncommon: myalgia
- increased creatine kinase.
- Rare: rhabdomyolysis β stop immediately.
- Uncommon: pancreatitis
- cholelithiasis.
- Rare: severe skin reactions
- hepatitis.
Precautions
- Contraindicated in severe renal impairment (eGFR < 30 mL/min).
- Contraindicated in severe hepatic impairment or active liver disease.
- Contraindicated in gallbladder disease.
- Avoid concomitant use with statins due to increased risk of myopathy/rhabdomyolysis.
- May enhance anticoagulant effect of warfarin β reduce warfarin dose and monitor INR.
- Monitor liver function and creatine kinase.
- Use with caution in renal impairment.
Indication
Fenoget 200 contains Fenofibrate, a fibric acid derivative lipid-lowering agent used as adjunct to diet for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia to reduce cardiovascular risk.
Ingredients
- Fenofibrate 200 mg (micronised)
Direction
Adults: 200 mg once daily orally with a meal. Swallow the capsule whole.
Side effects
- Common: nausea
- diarrhoea
- abdominal pain
- dyspepsia.
- Common: headache
- fatigue.
- Uncommon: myalgia
- increased creatine kinase.
- Rare: rhabdomyolysis β stop immediately.
- Uncommon: pancreatitis
- cholelithiasis.
- Rare: severe skin reactions
- hepatitis.
Precautions
- Contraindicated in severe renal impairment (eGFR < 30 mL/min).
- Contraindicated in severe hepatic impairment or active liver disease.
- Contraindicated in gallbladder disease.
- Avoid concomitant use with statins due to increased risk of myopathy/rhabdomyolysis.
- May enhance anticoagulant effect of warfarin β reduce warfarin dose and monitor INR.
- Monitor liver function and creatine kinase.
- Use with caution in renal impairment.
You may also like
Similar medicines from SETHIKA CARE Pharmacy
